M & J Western Regional Institute of Ophthalmology, Civil Hospital, Ahmedabad, Gujarat, India.
Department of Ophthalmology, The Sheth L.G Municipal Hospital, Maninagar, Ahmedabad, Gujarat, India.
Indian J Ophthalmol. 2022 Jun;70(6):2020-2023. doi: 10.4103/ijo.IJO_3145_21.
Ripasudil hydrochloride hydrate (0.4%) is the first Rho-associated protein kinase (ROCK) inhibitor eye drop that lowers intraocular pressure (IOP) by increasing conventional aqueous outflow through the trabecular meshwork and Schlemm's canal. We aimed to evaluate the safety and efficacy of ripasudil in patients using the maximum topical anti-glaucoma medications and with uncontrolled IOP.
In our prospective interventional study, we enrolled 27 eligible and consenting patients (46 eyes) who presented to us between January 2021 and June 2021. Ripasudil 0.4% was added as adjunctive therapy to the ongoing glaucoma treatment. On follow-up visits at 7 days, 15 days, 1 month, 2 months, and 3 months, the visual acuity, IOP with applanation tonometer, anterior segment, and fundus were evaluated. The IOP before and after the use of ripasudil eye drops was compared by paired t-test.
Among the 27 patients, 18 were males and 9 were females. A statistically significant reduction in IOP was noted at all time durations (P < 0.00001) with the maximum reduction at 3 months with all patients achieving their target IOP. No patient developed any side effects necessitating the omission of ripasudil. The most common adverse event noted was conjunctival hyperemia (22 patients), which was mild and transient.
Ripasudil showed additional IOP-lowering effect with other antiglaucoma medications and exhibited no significant side effects.
盐酸利匹司特水合物（0.4%）是第一种通过增加小梁网和施莱姆管的传统房水流出来降低眼内压（IOP）的 Rho 相关蛋白激酶（ROCK）抑制剂滴眼液。我们旨在评估 ripasudil 在使用最大剂量局部抗青光眼药物和眼压控制不佳的患者中的安全性和疗效。
在我们的前瞻性干预研究中，我们招募了 2021 年 1 月至 2021 年 6 月期间来我院就诊的 27 名符合条件并同意参加的患者（46 只眼）。将利匹司特 0.4%添加为正在进行的青光眼治疗的辅助治疗。在随访的第 7 天、第 15 天、第 1 个月、第 2 个月和第 3 个月，评估视力、眼压（压平眼压计）、眼前段和眼底。通过配对 t 检验比较使用利匹司特滴眼液前后的眼压。
在 27 名患者中，18 名男性，9 名女性。所有时间点的眼压均有统计学显著降低（P < 0.00001），3 个月时降低幅度最大，所有患者均达到目标眼压。没有患者因副作用而需要停用利匹司特。最常见的不良反应是结膜充血（22 例），为轻度和一过性。
利匹司特与其他抗青光眼药物联合使用具有额外的降眼压作用，且无明显副作用。
